Introduction:
Sandoz plans to open a new antibiotic production facility in Austria, Europe.
Features:
This state-of-the-art facility will boost the production capacity for crucial life-saving medicines.
The upcoming facility, alongside its automated production lines, will elevate the production capacity by 20 per cent from the current 200 million packages per year.
With this expansion, Kundl's production capacity will surge to 240 million packages annually, surpassing the output levels of 2021 by more than double.
With a manufacturing area spanning 3,000 square metres, the incorporation of innovative technologies facilitates the production of an additional one billion penicillin tablets and doubles the quantity of powder oral suspensions (POS), primarily utilised in paediatric medicines.
The new facility is a pivotal component of a €200 million investment into the Kundl site, geared towards a significant enhancement of penicillin API manufacturing and a consequent boost in the production of finished products.
This facility aims to enhance patient care in over 100 countries globally.
Specifications:
Name Sandoz
Type New Construction
